Science: psychedelic science, curated weekly

Every week our machine elves read every new psychedelic science paper on PubMed, every new preprint (via Europe PMC) and every trial registration on ClinicalTrials.gov. An editor picks the few that matter and says plainly how strong the evidence is: animal or human, controlled or not, peer reviewed or preprint.

The Science section has three parts: this week's issue, a searchable library of everything our machine elves have collected, and a research chat that answers questions from the literature and cites its sources.

This week: Ketamine trip intensity tracks depression gains

3,637 patients — but retrospective telehealth data can't separate dose from expectancy.

  1. Does the experience matter? Two more attempts
  2. Mescaline raises empathy, and ketanserin blocks it
  3. Psilocybin turns up as a CGRP inhibitor
  4. What is actually on the blotter
  5. In brief
  6. In the clinic
  7. On the preprint servers
—
Node—
Statuslive
Throughput—